ANI Pharmaceuticals Inc
F:BSFA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
ANI Pharmaceuticals Inc
F:BSFA
|
US |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
US |
|
C
|
Comerica Inc
F:CA3
|
US |
|
Esi SpA
MIL:ESIGM
|
IT |
|
L
|
L'Occitane International SA
XMUN:COC
|
LU |
|
A
|
AngioDynamics Inc
F:UG2
|
US |
|
S
|
Shanghai Electric Group Co Ltd
SWB:USR
|
CN |
|
Precision BioSciences Inc
F:PBS0
|
US |
Wall St Price Targets
BSFA Price Targets Summary
ANI Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for BSFA is 109.12 EUR with a low forecast of 89.1 EUR and a high forecast of 127.62 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BSFA's stock price target?
Price Target
109.12
EUR
According to Wall Street analysts, the average 1-year price target for BSFA is 109.12 EUR with a low forecast of 89.1 EUR and a high forecast of 127.62 EUR.
What is the Revenue forecast for ANI Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 14 years, the compound annual growth rate for Revenue has been 73%. The projected CAGR for the next 8 years is 8%.
What is the Operating Income forecast for ANI Pharmaceuticals Inc?
Projected CAGR
20%
The compound annual growth rate for Operating Income over the next 8 years is 20%.
What is the Net Income forecast for ANI Pharmaceuticals Inc?
Projected CAGR
20%
The compound annual growth rate for Net Income over the next 8 years is 20%.
